ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab

DRUG2 trials

Sponsors

Second Affiliated Hospital of Guangzhou Medical University

Conditions

AntibodyInoperable DiseaseLiver CancerLung Cancer

Phase 2

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

RecruitingNCT06482801

Second Affiliated Hospital of Guangzhou Medical UniversityAntibody, Liver Cancer

Start: 2024-06-10End: 2035-12-30Target: 90Updated: 2024-07-01

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

RecruitingNCT06483347

Second Affiliated Hospital of Guangzhou Medical UniversityInoperable Disease, Lung Cancer

Start: 2024-04-04End: 2033-12-30Target: 90Updated: 2024-07-03